-
Mashup Score: 0Voxelotor Improves Cerebral Hemodynamic Parameters in Pediatric Sickle Cell Disease - 2 month(s) ago
Voxelotor decreases oxygen extraction fraction and cerebral blood flow towards levels observed in healthy children.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
No concerning patterns of long-term or increasing opioid use were observed within 3 years after first opioid prescription in opioid-naive children with SCD.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Progress, Not Cure, for Sickle Cell Disease, Says Ethicist - 2 month(s) ago
Art Caplan discusses progress made for treating sickle cell disease and the importance of not labeling it as a cure.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
A meta-analysis revealed a higher prevalence of abnormal ECG findings in individuals with SCD compared to those without the disease.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 6
Background: Sickle cell disease (SCD) and its complications contribute to high rates of morbidity and early mortality and high cost in the United States and African heritage community. Objective: To evaluate the cost-effectiveness of gene therapy for SCD and its value-based prices (VBPs). Design: Comparative modeling analysis across 2 independently developed simulation models (University of Washington Model for Economic Analysis of Sickle Cell Cure [UW-MEASURE] and Fred Hutchinson Institute Sickle Cell Disease Outcomes Research and Economics Model [FH-HISCORE]) using the same databases. Data Sources: Centers for Medicare & Medicaid Services claims data, 2008 to 2016; published literature. Target Population: Persons eligible for gene therapy. Time Horizon: Lifetime. Perspective: U.S. health care sector and societal. Intervention: Gene therapy versus common care. Outcome Measures: Incremental cost-effectiveness ratios (ICERs), equity-informed VBPs, and price acceptability curves. Results
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 6
Background: Sickle cell disease (SCD) and its complications contribute to high rates of morbidity and early mortality and high cost in the United States and African heritage community. Objective: To evaluate the cost-effectiveness of gene therapy for SCD and its value-based prices (VBPs). Design: Comparative modeling analysis across 2 independently developed simulation models (University of Washington Model for Economic Analysis of Sickle Cell Cure [UW-MEASURE] and Fred Hutchinson Institute Sickle Cell Disease Outcomes Research and Economics Model [FH-HISCORE]) using the same databases. Data Sources: Centers for Medicare & Medicaid Services claims data, 2008 to 2016; published literature. Target Population: Persons eligible for gene therapy. Time Horizon: Lifetime. Perspective: U.S. health care sector and societal. Intervention: Gene therapy versus common care. Outcome Measures: Incremental cost-effectiveness ratios (ICERs), equity-informed VBPs, and price acceptability curves. Results
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 6
Background: Sickle cell disease (SCD) and its complications contribute to high rates of morbidity and early mortality and high cost in the United States and African heritage community. Objective: To evaluate the cost-effectiveness of gene therapy for SCD and its value-based prices (VBPs). Design: Comparative modeling analysis across 2 independently developed simulation models (University of Washington Model for Economic Analysis of Sickle Cell Cure [UW-MEASURE] and Fred Hutchinson Institute Sickle Cell Disease Outcomes Research and Economics Model [FH-HISCORE]) using the same databases. Data Sources: Centers for Medicare & Medicaid Services claims data, 2008 to 2016; published literature. Target Population: Persons eligible for gene therapy. Time Horizon: Lifetime. Perspective: U.S. health care sector and societal. Intervention: Gene therapy versus common care. Outcome Measures: Incremental cost-effectiveness ratios (ICERs), equity-informed VBPs, and price acceptability curves. Results
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 6
Background: Sickle cell disease (SCD) and its complications contribute to high rates of morbidity and early mortality and high cost in the United States and African heritage community. Objective: To evaluate the cost-effectiveness of gene therapy for SCD and its value-based prices (VBPs). Design: Comparative modeling analysis across 2 independently developed simulation models (University of Washington Model for Economic Analysis of Sickle Cell Cure [UW-MEASURE] and Fred Hutchinson Institute Sickle Cell Disease Outcomes Research and Economics Model [FH-HISCORE]) using the same databases. Data Sources: Centers for Medicare & Medicaid Services claims data, 2008 to 2016; published literature. Target Population: Persons eligible for gene therapy. Time Horizon: Lifetime. Perspective: U.S. health care sector and societal. Intervention: Gene therapy versus common care. Outcome Measures: Incremental cost-effectiveness ratios (ICERs), equity-informed VBPs, and price acceptability curves. Results
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3The State of Cell and Gene Therapy 2024 - 4 month(s) ago
Biopharma companies are witnessing a sea change in disease treatment and, in some cases, the development of cures due to the rapid pace of advances in cell and gene therapy. With currently 27 FDA-approved gene and cell therapy products and a plethora of candidates in development and clinical trials, gene and cell therapies are some of the fastest growing and financially attractive additions to the biomedical toolkit.In The State of Cell and Gene Therapy 2024, GEN proudly brings together a group of luminaries from industry and academia to discuss the latest research developments, innovations, and disruptive technologies that are impacting patients’ lives today and will spur cell and gene therapies to bigger and better things tomorrow. Among the highlights in this summit are:An opening keynote conversation with Peter Marks, MD, PhD (Center for Biologics Evaluation and Research at the FDA)A keynote presentation from gene therapy pioneer James Wilson, MD, PhD (UPenn)A panel on cell and gen
Source: webinars.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 3The State of Cell and Gene Therapy 2024 - 4 month(s) ago
Biopharma companies are witnessing a sea change in disease treatment and, in some cases, the development of cures due to the rapid pace of advances in cell and gene therapy. With currently 27 FDA-approved gene and cell therapy products and a plethora of candidates in development and clinical trials, gene and cell therapies are some of the fastest growing and financially attractive additions to the biomedical toolkit.In The State of Cell and Gene Therapy 2024, GEN proudly brings together a group of luminaries from industry and academia to discuss the latest research developments, innovations, and disruptive technologies that are impacting patients’ lives today and will spur cell and gene therapies to bigger and better things tomorrow. Among the highlights in this summit are:An opening keynote conversation with Peter Marks, MD, PhD (Center for Biologics Evaluation and Research at the FDA)A keynote presentation from gene therapy pioneer James Wilson, MD, PhD (UPenn)A panel on cell and gen
Source: webinars.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
In a new study, voxelotor significantly decreased oxygen extraction fraction and cerebral blood flow among children with #SickleCellDisease, similar to healthy levels. Learn more: https://t.co/uLYaNmkzjY